Warwick Effect Polymers Key PolyPEG Patent Granted in Europe
Warwick Effect Polymers (WEP), the biopolymer specialist company focusing on technologies to enhance biological drugs, announces that the key patent covering its PolyPEG®, next generation PEGylation technology has been granted in Europe.
The granted patent, EP1646661, protects WEP’s comb-shaped PolyPEG® polymers, the methods to produce them and conjugates formed by covalently attaching PolyPEGs® to biological entities, such as proteins, peptides and oligonucleotide therapeutics. The patent is granted in 11 key European countries, providing wide coverage in this important market.
WEP continues to progress the development and commercialisation of PolyPEG® as a novel and differentiated half-life extension strategy for biological therapeutics. Two key advantages of PolyPEG® polymers are their very low viscosity, enabling high concentration formulations to be produced for ease of administration to patients, and the absence of tissue accumulation, which is often seen with conventional PEGs.
Commenting on the grant of the patent, WEP’s Executive Chairman, Dr Richard Palmer said “The granting of this key patent in Europe reinforces the novelty of PolyPEG® and sets us on a firm footing for our continued commercialisation activities. We currently have agreements with numerous global pharmaceutical and biotechnology companies who are working with PolyPEG®, and WEP’s other proprietary technology GlycoPol™, to enhance their specific biological products. We expect to enter into further agreements over the next few months”.
The granted patent, EP1646661, protects WEP’s comb-shaped PolyPEG® polymers, the methods to produce them and conjugates formed by covalently attaching PolyPEGs® to biological entities, such as proteins, peptides and oligonucleotide therapeutics. The patent is granted in 11 key European countries, providing wide coverage in this important market.
WEP continues to progress the development and commercialisation of PolyPEG® as a novel and differentiated half-life extension strategy for biological therapeutics. Two key advantages of PolyPEG® polymers are their very low viscosity, enabling high concentration formulations to be produced for ease of administration to patients, and the absence of tissue accumulation, which is often seen with conventional PEGs.
Commenting on the grant of the patent, WEP’s Executive Chairman, Dr Richard Palmer said “The granting of this key patent in Europe reinforces the novelty of PolyPEG® and sets us on a firm footing for our continued commercialisation activities. We currently have agreements with numerous global pharmaceutical and biotechnology companies who are working with PolyPEG®, and WEP’s other proprietary technology GlycoPol™, to enhance their specific biological products. We expect to enter into further agreements over the next few months”.